Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) is -13.08% lower on its value in year-to-date trading and has touched a low of $76.02 and a high of $100.38 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BMRN stock was last observed hovering at around $83.87 in the last trading session, with the day’s loss setting it -0.06%.
Currently trading at $83.81, the stock is -4.02% and -6.73% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.4 million and changing -0.07% at the moment leaves the stock -6.36% off its SMA200. BMRN registered -10.28% loss for a year compared to 6-month gain of -4.93%. The firm has a 50-day simple moving average (SMA 50) of $6.55 and a 200-day simple moving average (SMA200) of $51.13.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -5.08% loss in the last 1 month and extending the period to 3 months gives it a -14.15%, and is -2.55% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.59% over the week and 2.29% over the month.
Biomarin Pharmaceutical Inc. (BMRN) has around 3401 employees, a market worth around $15.81B and $2.42B in sales. Current P/E ratio is 96.20 and Fwd P/E is 31.22. Profit margin for the company is 6.93%. Distance from 52-week low is 10.25% and -16.51% from its 52-week high. The company has generated returns on investments over the last 12 months (3.00%).
Biomarin Pharmaceutical Inc. quarterly earnings per share for the current quarter are estimated at $0.33 with sales reaching $650.74M over the same period.The EPS is expected to grow by 81.99% this year, but quarterly earnings will post 14.10% year-over-year. Quarterly sales are estimated to grow 9.10% in year-over-year returns.
Biomarin Pharmaceutical Inc. (BMRN) Top Institutional Holders
836 institutions hold shares in Biomarin Pharmaceutical Inc. (BMRN), with institutional investors hold 102.27% of the company’s shares. The shares outstanding are 188.60M, and float is at 184.71M with Short Float at 1.65%. Institutions hold 101.51% of the Float.
The top institutional shareholder in the company is Primecap Management Company with over 18.38 million shares valued at $1.59 billion. The investor’s holdings represent 9.77% of the BMRN Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 17.74 million shares valued at $1.54 billion to account for 9.43% of the shares outstanding. The other top investors are Dodge & Cox Inc which holds 14.29 million shares representing 7.59% and valued at over $1.24 billion, while Blackrock Inc. holds 7.45% of the shares totaling 14.02 million with a market value of $1.21 billion.
Biomarin Pharmaceutical Inc. (BMRN) Insider Activity
The most recent transaction is an insider sale by BIENAIME JEAN JACQUES,the company’sDirector. SEC filings show that BIENAIME JEAN JACQUES sold 1,000 shares of the company’s common stock on Mar 06 ’24 at a price of $86.71 per share for a total of $86713.0. Following the sale, the insider now owns 0.56 million shares.
Biomarin Pharmaceutical Inc. disclosed in a document filed with the SEC on Mar 05 ’24 that FUCHS HENRY J (President, Worldwide R&D) sold a total of 35,341 shares of the company’s common stock. The trade occurred on Mar 05 ’24 and was made at $85.18 per share for $3.01 million. Following the transaction, the insider now directly holds 0.21 million shares of the BMRN stock.
Still, SEC filings show that on Mar 05 ’24, Ajer Jeffrey Robert (EVP, Chief Commercial Officer) disposed off 4,000 shares at an average price of $87.07 for $0.35 million. The insider now directly holds 94,047 shares of Biomarin Pharmaceutical Inc. (BMRN).
